Hansa Biopharma enters into €115 million licensing ...
-
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
• The agreement covers the European Union, United Kingdom, Switzerland,
Norway, Liechtenstein, Iceland and the MENA region• Significantly enhances Hansa's financial position, ensuring a robust U.S.
launch and provides path to profitability, subject to US approval• SERB has a substantial European commercial presence and a successful
track record in critical care and rare disease commercialization
...
Renée Aguiar-Lucander, CEO of Hansa Biopharma, said “This agreement is transformative for Hansa Biopharma. It allows patients in the region to benefit from a partner with an established commercial footprint and proven growth track record in Europe. At the same time, it crystallizes the value of the franchise and significantly strengthens our financial position assuring an optimized US launch and a pathway to profitability, subject to a 2026 US approval, as well as the continued pursuit of our R&D pipeline.”
...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind